Translational Research Working Group Developmental Pathway for Immune Response Modifiers

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a se...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2008-09, Vol.14 (18), p.5692-5699
Main Authors: Cheever, Martin A, Schlom, Jeffrey, Weiner, Louis M, Lyerly, H Kim, Disis, Mary L, Greenwood, Addison, Grad, Oren, Nelson, William G
Format: Article
Language:English
Subjects:
Cancer Vaccines - therapeutic use
Clinical Trials as Topic
Humans
Immunologic Factors - therapeutic use
Immunotherapy - methods
National Institutes of Health (U.S.)
Neoplasms - therapy
Organization and Administration
Program Development
Software Design
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-08-1266